Table 1.
Baseline patient characteristics.
| Characteristics | N | No. of Patients (%) |
|---|---|---|
| Gender | ||
| Male | 41 | 33.6% |
| Female | 81 | 66.4% |
| Age | ||
| 65–75 | 74 | 60.7% |
| >75 | 48 | 39.3% |
| EOCG performance status | ||
| 0–1 | 64 | 52.5% |
| 2 | 58 | 47.5% |
| Histology | ||
| Adenocarcinoma | 102 | 83.6% |
| Adenosquamous | 9 | 7.4% |
| Squamous cell | 6 | 4.9% |
| NSCLC | 5 | 4.1% |
| EGFR mutation | ||
| Exon 19 deletion | 55 | 45.1% |
| Exon 21 L858R | 67 | 54.9% |
| Smoking status | ||
| Nonsmoker | 50 | 41.0% |
| Present or former smoker | 72 | 59.0% |
| Smoking Index | ||
| <600 | 71 | 58.2% |
| ≥600 | 51 | 41.8% |
| Comorbidity | ||
| No | 24 | 19.7% |
| Yes | 98 | 80.3% |
| Comorbidity type | ||
| Hypertension | 78 | 63.9% |
| Diabetes | 48 | 39.3% |
| COPD | 35 | 28.7% |
| CHD | 30 | 24.6% |
| Atrial Fibrillation | 21 | 17.2% |
| N stage | ||
| N0–1 | 57 | 46.7% |
| N2–3 | 65 | 53.3% |
| T stage | ||
| T1–2 | 63 | 51.6% |
| T3–4 | 59 | 48.4% |
| Second-line treatment | ||
| No | 58 | 47.5% |
| Yes | 64 | 52.5% |
| No. of metastases | ||
| 1–2 | 68 | 55.7% |
| 3–5 | 54 | 44.3% |
| Metastasis location | ||
| Brain | 62 | 50.8% |
| Bone | 59 | 48.3% |
| Lung | 42 | 34.4% |
| Adrenal | 35 | 28.7% |
| Liver | 9 | 7.40% |
| Non-region lymph nodes | 8 | 6.60% |
| PET-CT | ||
| No | 37 | 30.3% |
| Yes | 85 | 69.7% |
| LCRT for both PT and OS | ||
| No | 72 | 59.0% |
| Yes | 50 | 41.0% |
NSCLC, non-small cell lung cancer; Smoking Index, number of cigarettes smoked per day × years of smoking; ECOG PS, Eastern Cooperative Oncology Group Performance Status; COPD, Chronic Obstructive Pulmonary Disease; CHD, Coronary Heart Disease; CNS, Central Nervous System; BED, Biological Effective Dose; PET-CT, Positron Emission Tomography Computed Tomography; PT, Primary Tumor; OS, Oligometastatic Sites; LCRT, Local Consolidative Radiation Therapy; EGFR, Epidermal Growth Factor Receptor.